(MedPage Today) — One winner emerged from a direct comparison of direct oral anticoagulants (DOACs) for patients with acute venous thromboembolism, based on the COBRRA randomized trial.
Safety events favored apixaban (Eliquis) over rivaroxaban…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
